Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non‐Hodgkin and Hodgkin lymphoma

Metzger, Monika L.; Mauz‐Körholz, Christine

doi:10.1111/bjh.15789

Cited by 31 publications

(19 citation statements)

References 119 publications

(125 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent decades, improvements in the treatment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) have resulted in an increased survival rate of approximately 80% to 90%. Nevertheless, long-term survivors may experience several late adverse effects that may lead to premature morbidity and mortality ( 1 , 2 , 3 ). Cardiovascular diseases (CVDs), such as myocardial dysfunction, heart failure, myocardial infarction, and valvular disease, are among the most important adverse effects of mediastinal radiotherapy and/or anthracycline-containing chemotherapy, which can develop even decades after treatment initiation ( 1 , 4 , 5 , 6 ).…”

mentioning

confidence: 99%

Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors

Velde

Janus

Bowen

et al. 2021

JACC: CardioOncology

View full text Add to dashboard Cite

Background Long-term survivors of Hodgkin lymphoma (HL) and mediastinal non-Hodgkin lymphoma experience late adverse effects of radiotherapy and/or anthracycline-containing chemotherapy, leading to premature cardiovascular morbidity and mortality. Objectives The aim of this study was to identify markers for subclinical cardiovascular disease using cardiovascular magnetic resonance (CMR) in survivors of HL and non-Hodgkin lymphoma. Methods CMR was performed in 80 lymphoma survivors treated with mediastinal radiotherapy with or without anthracyclines, and results were compared with those among 40 healthy control subjects matched for age and sex. Results Of the 80 lymphoma survivors, 98% had histories of HL, the mean age was 47 ± 11 years, and 54% were male. Median radiotherapy dose was 36 Gy (interquartile range: 36-40 Gy), and radiotherapy was combined with anthracyclines in 70 lymphoma survivors (88%). Mean time between diagnosis and CMR was 20 ± 8 years. Significantly lower left ventricular (LV) ejection fraction (53% ± 5% vs 60% ± 5%; P < 0.001) and LV mass (47 ± 10 g/m 2 vs 56 ± 8 g/m 2 ; P < 0.001) and higher LV end-systolic volume (37 ± 8 mL/m 2 vs 33 ± 7 mL/m 2 ; P = 0.013) were found in lymphoma survivors. LV global strain parameters were also significantly worse in lymphoma survivors ( P < 0.02 for all). Native myocardial T1 was significantly higher in lymphoma survivors compared with healthy control subjects (980 ± 33 ms vs 964 ± 25 ms; P = 0.007), and late gadolinium enhancement was present in 11% of the survivors. Conclusions Long-term lymphoma survivors have detectable changes in LV function and native myocardial T1 on CMR. Further longitudinal studies are needed to assess the implication of these changes in relation to treatment and clinical outcome.

show abstract

mentioning

confidence: 99%

Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors

Velde

Janus

Bowen

et al. 2021

JACC: CardioOncology

View full text Add to dashboard Cite

show abstract

“…Meanwhile, improvements in linker design and antibody engineering have prompted a resurgence of antibody-drug conjugates [157], while similar advancements in radiation therapy have facilitated the exploration of new radioimmunotherapies [158,159]. Vaccines to promote tumor antigen presentation on dendritic cells continue to be studied as well [160]. Finally, adoptive cell therapies have ushered in a new era of cellular immunotherapy, with chimeric antigen receptor (CAR) Tcells approved for several B-cell neoplasms and numerous additional CAR-T and CAR-NK cell products under clinical investigation [97,98,161].…”

Section: Engaging the Antitumor Immune Responsementioning

confidence: 99%

Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma

Csizmar

Ansell

2021

IJMS

View full text Add to dashboard Cite

Immunotherapy has emerged as a powerful therapeutic strategy for many malignancies, including lymphoma. As in solid tumors, early clinical trials have revealed that immunotherapy is not equally efficacious across all lymphoma subtypes. For example, immune checkpoint inhibition has a higher overall response rate and leads to more durable outcomes in Hodgkin lymphomas compared to non-Hodgkin lymphomas. These observations, combined with a growing understanding of tumor biology, have implicated the tumor microenvironment as a major determinant of treatment response and prognosis. Interactions between lymphoma cells and their microenvironment facilitate several mechanisms that impair the antitumor immune response, including loss of major histocompatibility complexes, expression of immunosuppressive ligands, secretion of immunosuppressive cytokines, and the recruitment, expansion, and skewing of suppressive cell populations. Accordingly, treatments to overcome these barriers are being rapidly developed and translated into clinical trials. This review will discuss the mechanisms of immune evasion, current avenues for optimizing the antitumor immune response, clinical successes and failures of lymphoma immunotherapy, and outstanding hurdles that remain to be addressed.

show abstract

“…By blocking the binding of PD-L1 to PD-1 with an immune checkpoint inhibitor (anti-PD-L1 or anti-PD-1), T cells can affect and kill tumor cells. These drugs have shown promising results in the therapy of refractory or relapsed hematological malignancies, and, in particular, HD [71,[73][74][75].…”

Section: Checkpoint Inhibitorsmentioning

confidence: 99%

Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies

Tragiannidis

Groll

2021

Pediatr Drugs

View full text Add to dashboard Cite

Targeted therapies have emerged as innovative treatments for patients whose disease does not respond to conventional chemotherapy, and their use has widely expanded in the field of pediatric hematologic malignancies in the last decade. While they carry the promise of improved disease control and survival and are currently investigated in first-line treatment protocols for patients with poor prognostic markers, they are associated with a considerable incidence of specific toxicities, including cytokine-release syndrome, neurotoxicity, hepatotoxicity, nephrotoxicity, cardiotoxicity, endocrine adverse events, and infectious complications. Iatrogenic or secondary dysgammaglobulinemia is a main consequence of targeted therapies using monoclonal antibodies and other antibody-derived treatments that target specific antigens on lymphoid cells (blinatumomab, inotuzumab ozogamicin, rituximab), chimeric antigen receptor T cells, tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib) and, to a lesser extent, checkpoint inhibitors (pembrolizumab, nivolumab). This review discusses the diagnosis and incidence of secondary or iatrogenic dysgammaglobulinemia in children treated with targeted therapies for leukemias and lymphomas, and options for monitoring and treatment.

show abstract

Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non‐Hodgkin and Hodgkin lymphoma

Cited by 31 publications

References 119 publications

Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors

Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors

Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma

Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies

Contact Info

Product

Resources

About